Advances in Research on Lipid-Lowering Mechanisms of Eight Medicinal Plants

被引:0
|
作者
Yang, Huangqizi [1 ]
机构
[1] Jiangxi Univ Tradit Chinese Med, Sch Pharm, Nanchang 330004, Jiangxi, Peoples R China
关键词
Hyperlipidemia; Herbs; Lipid-Lowering Active Ingredients; Lipid-Lowering Mechanisms; INDUCED OXIDATIVE STRESS; INSULIN-RESISTANCE; BETA-CELL; GREEN TEA; HIGH-FAT; INTESTINAL-ABSORPTION; CISSAMPELOS-PAREIRA; ZINGIBER-OFFICINALE; ETHANOLIC EXTRACT; LEAF EXTRACT;
D O I
10.1063/1.5085520
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Hyperlipidemia is a disease of fat metabolism or abnormal operation in healthcare, characterized by one or more of high total cholesterol (TC), high triglycerides (TG), high low-density lipoprotein cholesterol (LDL-C) and low high-density lipoprotein cholesterol (HDL-C) in blood. Hyperlipidemia is prone to cardiovascular and cerebrovascular diseases, obesity, diabetes, hyperinsulinemia and other diseases, posing a serious threat to human health. However, the commonly used chemical synthetic lipid-lowering drugs have obvious clinical effects, but the effect is biased to single and adverse reactions, such as adverse reactions of the nervous system, gastrointestinal reactions and liver damage. In recent years, a large number of literatures had reported that various medicinal plants or their active ingredients had lipid-lowering effects. Thus, finding safe and effective lipid-lowering components from natural medicines has a broad development prospects in research. In this review, I tried to explore the information of several active components of lipid-lowering plants and their lipid-lowering mechanisms, which may help future researchers develop new natural lipid-lowering drugs to treat hyperlipidemia.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Pharmacogenetics of lipid-lowering drugs
    Kivisto, K. T.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2007, 37 : 47 - 47
  • [42] Lipid-lowering drugs and cataract
    Bezin, J.
    Mansiaux, Y.
    Pariente, A.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2017, 31 : 6 - 6
  • [43] Lipid-Lowering Agents and Hepatotoxicity
    Demyen, Michael
    Alkhalloufi, Kawtar
    Pyrsopoulos, Nikolaos T.
    CLINICS IN LIVER DISEASE, 2013, 17 (04) : 699 - +
  • [44] Complementary lipid-lowering therapies
    McDermott, JH
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1999, 56 (16) : 1668 - 1671
  • [45] Lipid-lowering therapies in development
    Wierzbicki, A. S.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 465 - 465
  • [46] Pharmacogenomics of lipid-lowering therapies
    Hu, Miao
    Tomlinson, Brian
    PHARMACOGENOMICS, 2013, 14 (08) : 981 - 995
  • [47] PRESCRIBING LIPID-LOWERING AGENTS
    WHEATLEY, G
    BRITISH JOURNAL OF GENERAL PRACTICE, 1995, 45 (395): : 329 - 329
  • [48] Carcinogenicity of lipid-lowering drugs
    Laws, A
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (19): : 1480 - 1480
  • [49] The Future of Lipid-Lowering Therapy
    van Zwol, Willemien
    Rimbert, Antoine
    Kuivenhoven, Jan Albert
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (07)
  • [50] Lipid-lowering efficacy of rosuvastatin
    Adams, Stephen P.
    Sekhon, Sarpreet S.
    Wright, James M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (11):